Correlation of serum fatty acid binding protein-4 and interleukin-6 with airflow limitation and quality of life in stable and acute exacerbation of COPD by اصلانی, محمدرضا et al.
337
http://journals.tubitak.gov.tr/medical/
Turkish Journal of Medical Sciences Turk J Med Sci
(2020) 50: 337-345
© TÜBİTAK
doi:10.3906/sag-1909-9
Correlation of serum fatty acid binding protein-4 and interleukin-6 with airflow 
limitation and quality of life in stable and acute exacerbation of COPD
Mohammad Reza ASLANI1,2, Zeynab GHAZAEI3, Hassan GHOBADI4,*
1Lung Inflammatory Diseases Research Centre, Faculty of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran
2Neurogenic Inflammation Research Centre, Mashhad University of Medical Sciences, Mashhad, Iran
3Faculty of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran
4Internal Medicine Department (Pulmonary Division), Faculty of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran
* Correspondence: h.ghobadi@arums.ac.ir 
1. Introduction
Chronic obstructive pulmonary disease (COPD) is one of 
the diseases that deeply affects morbidity and mortality 
in the world [1]. The limitation of air flow is the main 
characteristic of the disease, which is usually associated 
with airway inflammation [1]. On the other hand, acute 
exacerbation of COPD (AECOPD) is characterized by 
increased systemic inflammation, worsening of pulmonary 
function tests, increased sputum production, worsening of 
dyspnoea and cough, and reduced health-associated quality 
of life, all of which affect the patient’s survival [2]. Similar to 
other diseases that are not characterized by specific aetiology, 
various factors contribute to the pathogenesis of the disease, 
including abnormal immune responses, environmental and 
hormonal factors, and variable gene expression [3]. 
It has been well-known that under the conditions of 
AECOPD there is severe airway and systemic inflammation 
[4]. Additionally, systemic inflammatory markers and 
cytokines such as interleukin-6 (IL-6), IL-8, fibrinogen, 
α1-antitrypsin, myeloperoxidase, C-reactive protein 
(CRP), and tumor necrosis factor alpha (TNF-α) are 
high with COPD in the exacerbation phase [3,4]. Despite 
extensive evidence, the precise mechanism of systemic 
inflammation in AECOPD is not completely clear. It has 
been reported that a variety of markers and cytokines peak 
during AECOPD. 
Adipokines (also known as adipocytokines) are 
adipocyte-secreted protein mediators that not only 
regulate energy metabolism, but they also control 
inflammatory responses in many chronic diseases [5–7]. 
Much evidence has shown that adipokines are involved 
in the lung inflammatory diseases, such as asthma and 
COPD [8,9]. One of the recently suggested adipokines, 
fatty acid binding protein 4 (FABP-4) (also known as 
Background/aim: The serum fatty acid binding protein 4 (FABP-4) level increases in chronic inflammatory diseases. The present study 
aimed to examine serum FABP-4 and interleukin (IL)-6 levels in patients with stable and acute exacerbation of chronic obstructive 
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FABP-4 may be involved in the pathogenesis of COPD.
Key words: Chronic obstructive pulmonary disease, fatty acid binding protein 4, interleukin-6, airflow limitation
Received: 03.09.2019              Accepted/Published Online: 02.01.2020              Final Version: 09.04.2020
Research Article
This work is licensed under a Creative Commons Attribution 4.0 International License.
338
ASLANI et al. / Turk J Med Sci
adipocyte-protein 2 or aP2), is produced by various cells 
such as adipocytes, endothelial cells, and macrophages 
[10]. It has been shown that FABP-4 has a regulatory role 
in lipid and glucose homeostasis, reactive oxygen species 
(ROS) production, the inflammatory processes, and 
secretion of leukotrienes [11,12]. FABP-4 promotes the 
secretion of proinflammatory cytokines such as IL-6 and 
TNF-α which exacerbate the severity of the inflammatory 
diseases [13]. On the other hand, it has been shown that by 
inhibiting the expression of FABP-4 by pharmacological 
and genetic studies, many inflammatory signals are 
inhibited, including the production of inducible nitric 
oxide synthase (iNOS), cyclooxygenase 2 (COX-2), and 
inflammatory cytokines such as IL-6, IL-1β, TNF-α [14]. In 
animal studies with an allergic airway inflammation model 
in FABP-4-knockout mice, reduced levels of cytokines and 
inflammatory cells in the lung tissue have been shown 
[15]. In addition, elevated serum levels of FABP-4 have 
been reported in chronic inflammatory diseases, such 
as asthma, rheumatoid arthritis, hypertension, insulin 
resistance, obesity, cardiac dysfunction, type 2 diabetes, 
atherosclerosis, acute lung injury, and female stable COPD 
[16]. The present study was conducted to evaluate serum 
FABP-4 and IL-6 levels in men with stable and acute 
exacerbation of COPD. Another aim of this study was to 
evaluate the relationship between serum FABP-4 levels 
and the severity of disease based on Global Initiative for 
Chronic Obstructive Pulmonary Disease (GOLD) grades 
and clinical assessment of disease severity based on COPD 
Assessment Test (CAT) in patients with COPD.
2. Materials and methods
2.1. Study participants
In the current study, 90 subjects were divided into 3 groups 
including 30 patients with stable COPD (SCOPD), 30 
patients with acute exacerbation of COPD (AECOPD), 
and 30 healthy subjects who were enrolled from April 2017 
to March 2018. All subjects were male and matched for 
age. Patients with a diagnosis of SCOPD were recruited 
from a respiratory clinic and patients with AECOPD were 
selected from among those admitted to the emergency 
department of Ardabil Imam Khomeini Educational 
and Clinical Hospital, Ardabil, Iran. The control group 
consisted of subjects with normal spirometry with no 
respiratory symptoms who were selected from the same 
hospital who visited in other outpatient clinics.
The SCOPD and AECOPD were diagnosed according 
to the American Thoracic Society (ATS) guidelines 
[17]. The AECOPD refers to a sudden worsening of 
COPD symptoms in the form of shortness of breath, 
chronic worsening of the cough, and increased volume 
or discoloration of the phlegm. The inclusion criterion 
for COPD patients was a ratio of the forced expiratory 
volume in 1 s (FEV1) to forced vital capacity (FVC) < 70%. 
Exclusion criteria were the history of hospitalization in the 
previous 4 weeks, cardiac ischemia, chronic inflammatory 
diseases, infectious disease, diabetes, metabolic syndrome, 
chronic renal failure, and cancer.
The pulmonary function testing was performed using 
a spirometer (Chest Inc., 801, Tokyo, Japan) according to 
ATS guidelines under standard conditions. Pulmonary 
function and biochemical tests were conducted on the 
same day for SCOPD and control subjects, but for the 
AECOPD patients they were carried out one day after 
admission to the hospital. The GOLD grades and COPD 
assessment test (CAT) questionnaire were fully completed 
for all patients described previously [18]. 
2.2. Biochemical measurements
Approximately 3–5 mL of blood samples were taken from 
all patients to determine serum levels of FABP-4 and IL-
6. Serum FABP-4 and IL-6 concentrations were measured 
using a commercial kit (Crystal day, China) and an 
electrochemiluminescent method with an Elecsys 2010 
automated analyser (Roche Diagnostics). The results were 
reported as ng/mL.
2.3. Statistical analysis
The results are presented as mean ± standard deviation 
(SD), or median and 25th–75th percentiles. Continuous 
variables were compared using the student’s t-test. 
Comparison between groups was made by ANOVA 
test was performed with Tukey Kemar post hoc test; 
alternatively, the Kruskal–Wallis test; if significant, it 
was followed by the Mann–Whitney U test for post hoc 
analysis. Correlation coefficients were assessed using the 
Pearson’s (or Spearman rank order) correlation test. Linear 
regression analyses were performed using FABP-4 as 
dependent variable and IL-6, FEV1, cigarette history (pack/
year), GOLD grade, and Spo2 as independent variables. A 
value of P < 0.05 was considered significant. SPSS version 
16.0 (SPSS Inc., Chicago, IL, USA) and Graph Pad Prism 5 
software were used for statistical analysis. 
3.  Results
3.1. Baseline characteristics of study population
The study population consisted of 90 men, comprising 30 
control subjects, 30 patients with SCOPD, and 30 patients 
with AECOPD. In the control group the mean age was 
58.13 ± 7.36 years and that of the COPD group was 58.70 
± 8.01 years (P = 0.730) (Table 1). 
The serum FABP-4 levels were significantly higher 
in the AECOPD group than in the control and SCOPD 
groups (P = 0.000 for both, Figure 1a). In addition, 
there was a significant difference in FABP-4 serum level 
between SCOPD and control subjects (P = 0.010, Figure 
1a). Further, IL-6 results revealed higher levels of IL-6 in 
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AECOPD group than in control and SCOPD groups (P = 
0.000 for both, Figure 1b). On the other hand, serum levels 
of IL-6 in SCOPD group were higher than control subjects 
(P = 0.023, Figure 1b). 
3.2. Severity of chronic obstructive pulmonary disease 
and baseline characteristics of the study population
Baseline parameters of the study population for COPD 
severity based on GOLD grade are presented in Table 2. 
There were statistically significant differences in SpO2 (P 
= 0.003), smoking history (pack/year) (P = 0.002), CAT 
score (P = 0.000), FABP-4 level (P = 0.000), and IL-6 (P = 
0.000) between the COPD groups based on GOLD grade. 
However, we found no significant differences in age (P 
= 0.849) and BMI (P = 0.735) according to the stages of 
COPD.
All grade III-IV patients have higher levels of FABP-
4 and IL-6 than the patients with lower grades both in 
AECOPD and stable groups (P < 0.01 to P < 0.001, Table 
2). The AECOPD patients had higher FABP-4 and IL-6 
than stable patients in all COPD grades (P < 0.05 and P < 
0.001, respectively) (Figure 2a and 2b).
The results showed that in both AECOPD and SCOPD 
groups, CAT scores were statistically higher in GOLD 
grades III-IV compared to stages I-II (P = 0.000 for both) 
(Table 2).
3.3. Relationship between serum levels of fatty acid 
binding protein-4 plus IL-6 and parameters of pulmonary 
function
With regard to study parameters, serum FABP-4 levels 
were significantly associated with FEV1% predicted (r = –0.716, 
Table 1. Baseline characteristics of patients with COPD and control subjects.
Parameters
Control group COPD group
 (n = 30) SCOPD(n = 30)
AECOPD
(n = 30) P-value
Mean age (year) 58.13 ± 7.36 57.97 ± 9.27 59.43 ± 6.59 0.730
Body mass index (kg/m2) 26.29 ± 3.52 26.27 ± 4.83 24.47 ± 4.38 0.174
Pulmonary function test:
FEV1 (% of predicted) 90.33 ± 7.98 53.56 ± 23.20 34.04 ± 14.01 0.000
FVC (% of predicted) 85.40 ± 9.26 68.20 ± 22.26 49.53 ± 21.72 0.000
FEV1/FVC 86.70 ± 4.21 58.76 ± 9.77 55.08 ± 11.24 0.000
FABP-4 (ng/mL) 0.80 (0.70–0.90) 0.90 (0.80–1.20) 1.10 (1–1.40) 0.000
IL-6 (ng/mL) 53.50 (43–58) 56 (53–61) 90.50 (76–109) 0.000
Data are presented as mean ± SD or median (25th–75th percentiles). AECOPD: acute exacerbation of 
COPD, SCOPD: stable COPD, FEV1: forced expiratory volume in 1 s, FVC: forced volume capacity, FABP-
4: fatty acid binding protein 4, IL-6: interleukin 6.
Figure 1: Individual values and median (25th to 75th percentiles) 
of serum levels of (a): FABP-4 and (b): IL-6 in study groups. For 
statistical differences between control group and other groups: *; 
P < 0.05, ***; P < 0.001. For statistical differences between stable 
COPD with acute exacerbation of COPD: +++; P < 0.001. FABP-
4: fatty acid binding protein 4, IL-6: interleukin-6.
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P = 0.000; Figure 3a), FVC% predicted (r = –0.670, P = 0.000), 
GOLD grades (r = 0.603, P = 0.000), and smoking history 
(pack/year) (r = 0.619, P = 0.000; Figure 3b). There were 
also significant correlations between serum FABP-4 levels 
and CAT score (r = 0.639, P = 0.000), and SpO2 (r = –0.537, 
P = 0.000; Figure 3c) (Table 3).
Further, the results showed that there were significant 
associations between IL-6 and FEV1% predicted (r = –0.666, 
P = 0.000; Figure 3d), smoking history (pack/year) (r = 
0.644, P = 0.000; Figure 3e), and SpO2 (r = –0.640, P = 
0.000; Figure 3f). Interestingly, there were also significant 
correlations between serum levels of FABP-4 and IL-6 (r = 
0.692, P = 0.000; Figure g).
Finally, a multiple regression was run to predict 
FABP-4 from IL-6, CAT score, and Spo2. These variables 
significantly predicted FABP-4, with F (4, 55) = 30.88, 
P < 0.001, R2 = 0.692. The results showed that the most 
significant predictors of FABP-4 were IL-6 and CAT score 
(P < 0.01 and P < 0.001, respectively) (Table 4).
4. Discussion
In this study, serum FABP-4 and IL-6 levels were 
significantly elevated with disease severity based on GOLD 
grades in patients with stable and acute exacerbation of 
COPD. Further, the serum FABP-4 and IL-6 levels were 
significantly higher in patients with stages III-IV COPD 
Table 2. GOLD groups and baseline characteristics of the study population.
Variables
GOLD I-II GOLD III-IV
SCOPD AECOPD SCOPD AECOPD
Number 14 8 16 22
Age (year) 57.21 ± 9.20 60.50 ± 11.60 58.62 ± 9.59 59.05 ± 3.82
BMI (kg/m2) 25.46 ± 4.06 24.47 ± 4.21 26.98 ± 5.44 24.48 ± 4.53
Smoking (pack per year)
P1
P2
22 (20–28) 30 (15–58)
NS
32.5 (27–39)
NS
44.5 (35–78)
P < 0.01
P < 0.05
FEV1 (% predicted)
P1
P2
74.78 ± 13.50 52.98 ± 2.50P < 0.001
35.00 ± 9.68
P < 0.001
27.15 ± 9.08
P < 0.05
P < 0.001
FVC (% predicted)
P1
P2
87.64 ± 14.69 70.75 ± 5.95
P < 0.01
51.18 ± 10.48
P < 0.001
41.82 ± 20.14
NS
P < 0.001
FEV1/FVC (%)
P1
P2
65.00 ± 3.16 58.97 ± 5.62
P < 0.01
53.31 ± 10.40
P<0.001
53.66 ± 12.49
NS
NS
SpO2 (%)
P1
P2
96 (92–96) 89 (85.50–89.50)P < 0.001
92 (89–95)
P < 0.05
85.50 (81–88)
P < 0.001
P < 0.05
CAT score
P1
P2
11 (9–16) 14 (13–15)NS
27 (21.50–31)
P < 0.001
26.5 (22–28)
NS
P < 0.001
IL-6 (ng/mL)
P1
P2
53.50 (51–56) 67 (63.50–80)P < 0.001
61 (55.50–85)
P < 0.01
102 (86–120)
P < 0.001
P < 0.01
FABP-4 (ng/mL)
P1
P2
0.80 (0.70–0.90) 1 (0.90–1)P < 0.01
1.10 (0.90–1.25)
P < 0.01
1.25 (1.10–1.60)
P < 0.05
P < 0.001
Data are depicted as mean ± SD or median (25th to 75th percentiles). GOLD: the Global Initiative for Chronic 
Obstructive Lung Disease, SCOPD: stable of chronic obstructive pulmonary disease, AECOPD: acute exacerbation 
of chronic obstructive pulmonary disease, BMI: body mass index, FEV1: forced expiratory volume in 1 s, FVC: 
forced volume capacity, SpO2: O2 saturation, FABP-4: fatty acid binding protein 4, IL-6: interleukin-6, CAT: COPD 
assessment test, NS: nonsignificant. P1: statistical differences between SCOPD with AECOPD groups. P2: statistical 
differences between GOLD I-II with GOLD III-IV in study groups. 
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than in stages I-II according to GOLD grade. There was 
a negative correlation between serum FABP-4 levels and 
SpO2 as well as with FEV1. On the other hand, there was a 
positive correlation between serum FABP-4 levels and IL-6 
as well as with severity of COPD based on GOLD grade. 
The main symptom of COPD, especially its acute 
exacerbation phase, is the high level of inflammation 
that plays a key role in the development of disease [3]. 
It has been shown that in patients with SCOPD and 
AECOPD there is an over-production of various types 
of inflammatory cytokines such as IL-6, TNF-α, and 
IL-1β, likely to stimulate downstream of cytokines to 
exacerbate pulmonary tissue damage [3, 19]. IL-6 is a 
pro-inflammatory cytokine produced predominantly by 
a variety of pulmonary cells, including airways epithelial 
cells, endothelial cells, alveolar macrophage, and fibroblast 
[20]. Our results indicated that serum IL-6 levels of 
AECOPD patients were higher than those in healthy 
subjects. In addition, it was found that the amount of IL-6 
serum levels in AECOPD of patients were higher than 
those in SCOPD patients. Also, the results of IL-6 serum 
levels based on the severity of the disease revealed that in 
stages III-IV the amount of IL-6 was higher than stages 
I-II, which was in line with previous studies [20]. 
Many studies have shown that a variety of adipokines 
play an important role in chronic inflammatory diseases 
such as asthma and COPD [13, 21]. Indeed, adipokines 
are modulating mediators of inflammatory and immune 
responses [22]. FABP-4, as adipokine, is a cytosolic 
protein that is involved in the lipid trafficking and 
signalling [23]. Many evidence reported that elevated 
FABP-4 concentrations have been associated with 
insulin resistance, obesity, asthma, hypertension, cardiac 
dysfunction, type 2 diabetics, atherosclerosis, acute lung 
injury, and stable COPD [16]. It has been indicated 
that FABP-4 has a regulatory role in the allergic airway 
inflammation and that blocking FABP-4 causes a decline 
in airway inflammation in lung diseases [15]. However, 
there are few studies about the association of FABP-4 with 
COPD severity of disease, especially in acute exacerbation 
phase. Zhang et al. revealed that there was a gender 
difference in serum FABP-4 level in patients with stable 
COPD [13]. In their study, it was found that in patients 
with stable COPD, the serum level of FABP-4 in females 
was higher than that in males and correlated negatively 
with pulmonary function tests and positively with TNF-α, 
CRP, and adiponectin levels [13]. In the current study, we 
found that the serum FABP-4 level in male patients with 
SCOPD was higher than control subjects. Although it 
is not clear to us whether there is a statistical difference 
between the levels of FABP-4 in men in our study and the 
study of Zhang et al., it seems that in our study, the higher 
BMI may have an effect on FABP-4 results, which requires 
further studies. 
Our results also showed that serum FABP-4 level was 
higher in patients with AECOPD than in healthy subjects 
as well as SCOPD patients. In fact, these results indicate 
that FABP-4 may play a critical role in the development 
of COPD. Previous studies have reported that FABP-4 
worsens inflammatory responses in inflammatory diseases 
by increasing levels of inflammatory cytokines or by 
recruiting inflammatory cells [24]. Perhaps FABP-4 plays 
a key role in the pathogenesis of COPD in the activation 
of transcription factors and release of inflammatory 
factors in macrophages. Since smoking has been shown 
to induce and activate macrophages, due to the strong 
correlation between FABP-4 and smoking in our study, 
at least in part, it can reflect the role of macrophages and 
their relationship with FABP-4 in pathogenesis of disease, 
especially in AECOPD condition. Animal studies have 
Figure 2: Serum levels of (a): FABP-4 and (b): IL-6 based on 
GOLD grade in stable and acute exacerbation of COPD patients. 
Data are depicted as median and quartiles range.  GOLD: the 
Global Initiative for Chronic Obstructive Lung Disease, SCOPD: 
stable of chronic obstructive pulmonary disease, AECOPD: acute 
exacerbation of chronic obstructive pulmonary disease, FABP-4: 
fatty acid binding protein 4, IL-6: interleukin-6.
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Figure 3: Spearman rank order correlation analysis of (a): FEV1 and FABP-4 serum levels (correlation coefficient = –0.716, P = 0.000), 
(b): smoking history and FABP-4 serum levels (correlation coefficient = 0.619, P = 0.000), (c): O2 saturation and FABP-4 serum levels 
(correlation coefficient = –0.537, P = 0.000), (d): FEV1 and IL-6 serum levels (correlation coefficient = –0.666, P = 0.000), (e): smoking 
history and IL-6 serum levels (correlation coefficient = 0.644, P = 0.000), (f): O2 saturation and IL-6 serum levels (correlation coefficient 
= –0.640, P = 0.000), and (g): serum levels of FABP-4 and IL-6 (correlation coefficient = 0.692, P = 0.000). FEV1: forced expiratory 
volume in 1 s, FABP-4: fatty acid binding protein 4, IL-6: interleukin-6, SpO2: O2-saturation.
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revealed that FABP-4-deficient macrophages have reduced 
inflammatory function and decreased inflammatory 
cytokines, such as IL-6, TNF-α, and MCP-1 [monocyte 
chemoattractant protein 1] [25]. In fact, mechanically, 
pharmacological or genetic inhibitors of FABP-4 had 
protective effects against inflammation through diminished 
chemokine and cytokine secretion, polarization of cells 
towards antiinflammatory M2 condition, and production 
suppression of proinflammatory factors in hepatic tissue 
[11,26,27]. In addition, our study results showed that there 
was a strong correlation between FABP-4 and IL-6 levels 
in patients with COPD, suggesting that adipokines such as 
FABP-4 may play a critical role in systemic inflammation 
of COPD patients. Particularly, the results revealed that 
serum levels of FABP-4 and IL-6 in the AECOPD patients 
were much higher than those in SCOPD patients. On 
the other hand, serum levels of FABP-4 in patients with 
AECOPD based on the severity of the disease in stages 
III-IV were greater than stages I-II, indicating that FABP-
4 plays a major role in the development and persistence 
of inflammation in patients with COPD. Accordingly, 
increased levels of FABP-4 in patients with COPD can be 
indicative of local or systemic inflammation. Although 
adipose tissue and inflammatory cells such as macrophage 
are the main secretor sources of FABP-4, it has also been 
shown that levels of FABP-4 are high in acute lung injury 
[28]. Of course, it should be noted that the authors did 
not rule out other pathways other than the inflammatory 
pathway of FABP-4 in patients with COPD. In patients 
with rheumatoid arthritis, it has been shown that increased 
levels of FABP-4 were associated with lipid profiles, 
independent of the severity of the disease, which indicates 
the predominant role of FABP-4 in lipid metabolism rather 
than inflammation pathway [14]. 
A significant negative correlation between SpO2 
and FABP-4 levels in our study may reveal another 
pathophysiological role of FABP-4 in COPD patients. In 
patients with COPD, one of the pathways activated as a 
result of hypoxia is endoplasmic reticulum stress response 
(ER stress). It has been shown that diminished FABP-
4 can reduce the apoptosis mediated by ER stress [29]. 
Therefore, elevated FABP-4 level in patients with COPD, 
especially in the AECOPD phase may have an effect on ER 
stress markers and may affect oxygenation changes which 
required further studies. 
In this study, we additionally found a positive 
association between serum FABP-4 levels and CAT score 
plus mMRC scales. It has been reported that physical 
activity significantly decreases in patients with higher 
stages of COPD [30]. Another study also proposed that 
the increase in levels of inflammatory factors such as 
C-reactive protein, IL-6, and fibrinogen is the main cause 
for this diminished activity [31]. The rise in serum FABP-
4 and IL-6 levels with increasing GOLD grades of COPD 
could correlate with the effect of systemic inflammation 
on health status.
Our study had some limitations. Since previous studies 
have shown that there was sex differences in FABP-4 
levels, we did not measure serum FABP-4 levels in female 
patients with COPD in the acute exacerbation phase. 
Further, we did not measure other inflammatory markers 
other than IL-6. Therefore, we are not able to determine 
the correlation between serum levels of FABP-4 and other 
inflammatory markers of COPD. Finally, the sample size 
of our study was small, and such evaluations should be 
performed with a large sample size. 
In conclusion, in this study, we found that serum 
FABP-4 and IL-6 levels increases with the enhanced 
GOLD grades in patients with COPD, markedly in acute 
Table 3. Spearman correlation analysis of study parameters with 
FABP-4 in COPD patients (n = 60)
FABP-4
Variables
P-valueR
0.5990.069Age
0.0000.608Smoking history (per year)
0.000–0.672FEV1 (% predicted)
0.000–0.651FVC (% predicted)
0.060–0.242FEV1/FVC
0.0000.603GOLD grade 
0.000–0.537SpO2
0.0000.693CAT score
FEV1: forced expiratory volume in 1 s, FVC: forced volume 
capacity, FABP-4: fatty acid binding protein 4, IL-6: interleukin 
6, SpO2: O2 saturation, GOLD: the Global Initiative for Chronic 
Obstructive Lung Disease, CAT: COPD assessment test.
Table 4. Associations between FABP-4 and study parameters.
FABP-4
Variables B 95% CI for B P-value
Spo2 –0.059 –0.013–0.007 0.538
IL-6 0.420 0.001–0.002 0.001
CAT score 0.361 0.007–0.021 0.000
Cigarette smoking 0.172 –0.000–0.006 0.093
B: unstandardized coefficient. CI: confidence intervals, FABP-
4: fatty acid binding protein 4, IL-6: interleukin-6, SpO2: O2 
saturation.
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exacerbation phase. The increase of FABP-4 had a strong 
relationship with elevated serum level of IL-6 and severity 
of hypoxia. Thus, serum FABP-4 levels merit consideration 
as a useful marker in the pathogenesis of COPD patients.
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